Blog

Nelson Advisors has been interviewed by Adriel Bettelheim at Axios for his story 'AI turns to health care for an image fix'Source: <a href="https://www.axios.com/2026/08/31/ai-health-care-cures-disease-anthropic-open-ai" data-mce-href="https://www.axios.com/2026/08/31/ai-health-care-cures-disease-anthropic-open-ai">https://www.axios.com/2026/08/31/ai-health-care-cures-disease-anthropic-open-ai</a>AI has an image problem. And one way to fix it is for top companies to dive headlong into health care.Why it matters: Saving the world with AI-designed cures is better than being blamed for ruining the environment or driving up Americans' utility bills.But even the most advanced AI models can't produce miracle treatments at the moment — and could create serious security risks if they try. That could set up a fraught debate over the next two or three years about the allocation of resources and whether the benefits of throwing vast amounts of computing capacity into medical research outweigh the costs. Driving the news: The Wall Street Journal reported this month that Anthropic was trying to shore up investor confidence ahead of its massive initial public offering with talk of pushing harder into health care and biology.CEO Dario Amodei wrote on X that Anthropic is moving quickly in biology and medicine "and we hope to have incredible results in the coming years and some early glimmers in the coming months." Anthropic isn't alone: Nvidia and Eli Lilly are building a $1 billion drug discovery lab in San Francisco that will team up life science researchers with AI model builders and engineers. Isomorphic Labs, the AI drug discovery spinoff from Google, recently raised $2.1 billion to hire more AI and clinical talent and has ongoing research collaborations with Novartis, Lilly and Johnson &amp; Johnson. Yes, but: Breakthroughs may still be years away. That's hardly reassuring to an increasingly anxious U.S. public that's gone NIMBY against data centers, with moratoriums, threatened lawsuits and fears of AI models taking more jobs.The technology is dramatically speeding up drug development and helping clinicians analyze medical scans and diagnose conditions. But it's also making health care more expensive, with software and scribes that more thoroughly document the care that's delivered. There also are concerns that AI-enabled research tools could be used for nefarious purposes, including potentially making a biological weapon. Anthropic implemented strict safeguards on its next-generation Claude Fable 5 model after concluding it could provide "significant uplift" to a bad actor. Between the lines: AI's push into health care comes as frontier labs like Anthropic and OpenAI prepare to go public to help cover the huge cost of training new models and maintaining multi-gigawatt computing infrastructures.Moving into the life sciences is a way to both diversify the companies' revenue streams and reshape public sentiment, said Lloyd Price, a partner at Nelson Advisors, a digital health M&amp;A firm."It's a bit of a hearts-and-minds play ... the bad guys are stealing all of the resources but they could help humanity. The truth is very in the middle," Price told Axios. Price said real medical advances could transform people's perception of AI from an environmental and security risk into an essential public utility. Friction point: There still are big hurdles ahead, including rocky relations with the Trump administration, which is trying to take a hands-off regulatory approach while maintaining oversight of safety and privacy concerns.What's more, the public isn't wild about big drug companies, believing their profits are a big factor in high drug prices. An AI company could face backlash if the public thinks it's putting profits ahead of patients and contributing to the affordability crisis. The bottom line: AI labs will need to prove they're bringing measurable benefits to society, not just satisfying investors. The question is whether the public will put up with more server farms in their backyards to get there."What I hear a lot is, where is the material contribution or breakthrough that's directly led to a drug discovery? It's a team sport, and AI is just a player on the field," Price said.Adriel Bettelheim is senior health care editor at Axios and oversees Vitals and Axios Pro Health Policy. He has also worked at Politico, Bloomberg and CQ Roll Call.<a href="https://www.axios.com/authors/abettelheim">https://www.axios.com/authors/abettelheim</a>

Nelson Advisors interviewed by Axios

This Week in European HealthTech, MedTech and Health AI: 28th August 2026.Funding rounds, clinical AI deployments and regulatory policy shifts dominate European HealthTech developments: &nbsp;&nbsp; Funding and Clinical Workflow Platforms: Venture capital continues to concentrate in clinical backend operations and interoperability. Following significant mid-market rounds across the UK and Nordics, enterprise care orchestration tools and administrative AI platforms are gaining major institutional support to reduce provider burnout and streamline electronic health record (EHR) integration.Domain-Specific AI vs. General LLMs: Health systems across the UK, Germany, and the Nordics are increasingly shifting procurement toward domain-specific clinical models rather than general-purpose LLMs.Danish AI diagnostics firm Corti's specialised clinical coding model demonstrated higher diagnostic and administrative accuracy than frontier general models, accelerating the adoption of vertical healthcare AI in European hospital networks.MDR/IVDR &amp; AI Act Implementation Pressures: The MedTech sector is actively pushing for revisions to the EU AI Act's "Digital Omnibus" and Medical Devices Regulation (MDR) frameworks. To prevent innovation migration to the US or Asia, European regulatory bodies are accelerating EU-level regulatory sandboxes, enabling software and device makers to test AI models in supervised, real-world clinical environments prior to full CE conformity assessments.Procurement and Reimbursement Harmonization: Public health authorities across Western Europe are updating digital health reimbursement criteria. Germany's DiGA ecosystem and France's PECAN framework continue expanding reimbursement for digital therapeutics and remote monitoring, while the UK’s MHRA progresses its "International Reliance" pathway to streamline regulatory recognition for overseas-approved medical software.Oncology &amp; Diagnostics Expansion: Next-generation diagnostics startups (covering liquid biopsy, breath analytics, and AI-accelerated radiology/pathology) secured fresh early-stage rounds across Paris, London, and Munich, backed by cross-border funding from the European Innovation Council (EIC) and specialised venture firms.EU Joint Research Centre (JRC) Disease Surveillance Framework: The European Commission’s JRC published an exploratory roadmap testing Generative AI and Retrieval-Augmented Generation (RAG) models to synthesise fragmented epidemiological data and generate rapid outbreak intelligence. The framework recommends a phased regional rollout via public health agencies with mandatory human-in-the-loop oversight to curb hallucinations and ensure cross-border data interoperability.Cardiovascular Biomarker Screening via Routine Mammography: Presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, researchers unveiled a deep-learning AI model that detects early markers of common cardiovascular diseases—including hypertension, ischaemic heart disease, and stroke—from standard breast cancer mammograms, providing non-invasive opportunistic screening for midlife women.EU AI Act &amp; Digital Omnibus Timeline Integration: Following recent adjustments under the EU Digital Omnibus, European health systems and MedTech developers received finalized guidance on high-risk medical AI. While strict transparency and disclosure rules now govern patient-facing clinical chatbots, embedded diagnostic AI obligations have been harmonized with the Medical Devices Regulation (MDR) transition timelines, deferring duplicate compliance burdens.Genomic Data Infrastructure (GDI) Operational Scaling: Cross-border infrastructure initiatives reached active milestones across 15 European member states, expanding federated access to secure genomic and multi-omic datasets designed specifically for training clinical diagnostic AI without centralising sensitive patient data.MDR/IVDR Risk-Adaptive Surveillance Reform: European notified bodies and the European Commission advanced proposals to transition away from rigid certificate expiration periods in favor of periodic, risk-proportionate post-market surveillance. Under the framework, manufacturers demonstrating sustained clinical compliance and post-market safety can qualify for stepwise reductions in notified-body audit intensity after three to six years.UK MHRA International Reliance Pathway: The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) progressed draft regulations establishing an "International Reliance" framework. The mechanism allows device makers with existing market authorizations from comparable regulators (including the US FDA, Health Canada, and Australia’s TGA) to fast-track medical device registration and market entry into Great Britain.Capital Shifts Toward Clinical Hardware &amp; Wearable Diagnostics: Late-summer venture investment prioritised clinical-grade device hardware and sensor platforms over pure software:Xeltis (Netherlands): Secured €20.5 million to advance its bioresorbable polymer cardiovascular implant technology.Onalabs (Spain): Raised €9.3 million Series A to scale non-invasive, skin-wearable sensors for continuous sweat-based biomarker monitoring.Ahead Health (Switzerland): Closed €8.7 million to expand preventive whole-body MRI hardware and screening centers.Transatlantic Supply Chain &amp; Tariff Protections: Industry group MedTech Europe welcomed the formal implementation of EU measures under the EU–US trade agreement framework, establishing capped tariff structures on critical medical technology hardware, surgical systems, and component exports to stabilise supply chains.Value-Based Procurement Push: Hospital networks and national health services in the DACH region and Nordics initiated new procurement guidelines shifting tender evaluations from lowest-purchase-price criteria to total cost of care, device resilience, and supply chain security. Nelson Advisors &gt; European HealthTech, MedTech, Digital Health Investment Banking &nbsp; &nbsp;Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk" data-mce-href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>&nbsp; Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis &amp; predictions @ <a href="https://www.healthcare.digital" data-mce-href="https://www.healthcare.digital">https://www.healthcare.digital</a>Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! <a href="https://lnkd.in/e5hTp_xb" data-mce-href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk" data-mce-href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics&nbsp; &nbsp; Nelson Advisors LLP &nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk﻿</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>

This Week in European HealthTech, MedTech and Health AI: 28th August 2026

Hugging Face has established itself as a central pillar of global artificial intelligence infrastructure, hosting over three million public models, one million datasets and one million applications. Founded in 2016 by French entrepreneurs Clément Delangue, Julien Chaumond, and Thomas Wolf as a consumer chatbot application, the enterprise pivoted to build the foundational repository and distribution hub for open-source machine learning.&nbsp; &nbsp;&nbsp; The company is exploring a potential acquisition that could value the platform at $13 billion or more, engaging investment banking advisors to sound out strategic acquisition interest across the technology sector. &nbsp;&nbsp; This valuation trajectory represents a nearly threefold expansion beyond the $4.5 billion post-money valuation established during its $235 million Series D funding round in August 2023. The 2023 round assembled a syndicate of enterprise technology giants and compute providers, including Google, Amazon Web Services (AWS), Nvidia, Salesforce Ventures, Intel, Qualcomm, IBM, Sequoia Capital and Lux Capital.&nbsp; &nbsp;&nbsp; Prior to this phase, the platform experienced significant valuation growth, scaling from a 2022 valuation pegged at approximately 100 times its annualised revenue to its current position as a essential market intermediary.The exploration of an outright sale marks a notable shift in corporate strategy for Chief Executive Officer Clément Delangue. Delangue previously maintained a stance on corporate independence, rejecting a $500 million strategic investment offer from Nvidia that would have valued the platform at $7 billion, explicitly citing a preference for an initial public offering (IPO) path over an early trade sale.&nbsp; &nbsp;&nbsp; However, macro-level consolidation across the AI distribution layer, most visibly illustrated by Stripe’s $7.5 billion to $8 billion acquisition of model routing platform OpenRouter, has redefined the financial logic governing aggregation platforms. &nbsp;&nbsp; As model hosting platforms move from passive hosting environments to active control planes for enterprise model routing, token optimisation and specialised domain workflows, market valuations have decoupled from traditional revenue multiples to reflect systemic utility and developer network effects. This structural evolution is reinforced by Hugging Face’s aggressive expansion into software execution and hardware tooling, exemplified by its acquisition of humanoid robotics firm Pollen Robotics, alongside core developer tools including Gradio, XetHub, and Argilla.Click here to read the report in full <a href="https://www.healthcare.digital/single-post/strategic-analysis-of-hugging-face-valuation-dynamics-enterprise-infrastructure-and-bio-medical-ai">https://www.healthcare.digital/single-post/strategic-analysis-of-hugging-face-valuation-dynamics-enterprise-infrastructure-and-bio-medical-ai</a>

Strategic Analysis of Hugging Face: Valuation Dynamics, Enterprise Infrastructure and Bio-Medical AI Expansion

The digital health sector experienced a major strategic realignment following regulatory disclosures detailing Sword Health Technologies' pending acquisition of Headspace, Inc. Formally submitted via a Material Change Notice (MCN) to the Massachusetts Health Policy Commission (HPC) on August 6th, 2026, the transaction is structured as an all-cash deal that unites an artificial intelligence-driven physical health platform with one of the industry's most widely recognised behavioural care brands. &nbsp;&nbsp; The regulatory review was triggered under state oversight statutes governing healthcare provider affiliations that increase Net Patient Service Revenue (NPSR) by more than $10 million within Massachusetts.&nbsp; &nbsp;&nbsp; With a target closing date set for September 14th, 2026, the transaction represents a pivotal structural shift in the post-pandemic digital health market. It marks a definitive move away from single-category point solutions toward unified, multi-modal enterprise platforms capable of delivering comprehensive care across physical and psychological domains.This acquisition reflects a broader consolidation trend driven by venture market adjustments, declining capital availability for standalone applications, and increased corporate demand for vendor rationalization. By absorbing Headspace, Sword Health accelerates its expansion from musculoskeletal (MSK) care into a platform covering physical therapy, pelvic health, surgical prehabilitation, continuous stress management, coaching, and clinical telepsychiatry.Click here to read the report in full <a href="https://www.healthcare.digital/single-post/strategic-platform-consolidation-in-digital-health-analysing-sword-health-s-acquisition-of-headspac">https://www.healthcare.digital/single-post/strategic-platform-consolidation-in-digital-health-analysing-sword-health-s-acquisition-of-headspac</a>

Strategic Platform Consolidation in Digital Health: Analysing Sword Health's Acquisition of Headspace

On August 25th, 2026, Radiology Partners, Inc. (RP), the largest physician-led and private equity backed radiology practice in the United States, entered into a definitive agreement to acquire Everlight Radiology (Everlight), a premier international teleradiology provider. While formal financial terms were withheld in the joint corporate announcement, financial reporting indicates the enterprise transaction is valued at approximately $1 billion (equivalent to AUD 1 billion).&nbsp; &nbsp;&nbsp; This transaction marks the divestment of Everlight by Livingbridge, the UK-based private equity firm that held majority ownership of the business since 2021 following its buyout from Intermediate Capital Group (ICG). &nbsp;&nbsp; The cross-border transaction unifies two giant entities in remote diagnostic imaging: RP's domestic teleradiology platform, vRad (Virtual Radiologic), and Everlight's cross-continental network. RP currently serves more than 3,400 U.S. hospitals and health systems, incorporating a network of thousands of radiologists accounting for nearly 10% of total U.S. diagnostic imaging volume. Everlight brings a network of over 800 consultant radiologists operating across 40 countries, delivering more than 2.5 million diagnostic reports annually to 340-plus client organisations across the United Kingdom, Ireland, Australia, New Zealand, and South Africa. &nbsp;&nbsp; The legal and financial execution of the deal reflects a high-stakes institutional advisory structure. Barclays and Rothschild &amp; Co. acted as financial advisors to Radiology Partners, with legal counsel provided by Kirkland &amp; Ellis and Jones Day. Everlight's executive leadership, under Global Chief Executive Officer Rob Anderson, will continue to direct day-to-day operations and manage client relationships independently post-closing, preserving regional clinical governance while integrating technological and operational infrastructure. The integration strategy hinges on maintaining strict local regulatory compliance, where radiologists read exclusively within jurisdictions where they hold active licensure and credentialing, while unifying backend worklist distribution, subspecialty load balancing and proprietary artificial intelligence deployment.Click here to read the report in full <a href="https://www.healthcare.digital/single-post/global-consolidation-in-ai-enabled-teleradiology-strategic-analysis-of-radiology-partners-1-billi">https://www.healthcare.digital/single-post/global-consolidation-in-ai-enabled-teleradiology-strategic-analysis-of-radiology-partners-1-billi</a>

Global Consolidation in AI-Enabled Teleradiology: Strategic Analysis of Radiology Partners' $1 Billion Acquisition of Everlight Radiology

The digital health ecosystem has transitioned into a mature phase characterised by institutional capital discipline, platform consolidation and rigorous operational scrutiny. Following the capital surge of 2025, during which venture funding in United States digital health startups rebounded to $14.2 billion across 482 completed deals, the market has undergone a structural transformation. Artificial intelligence (AI), which commanded 54% of all digital health venture capital in 2025, has shifted from a novel marketing narrative into an operational baseline. By the first half of 2026, market intelligence platforms ceased tracking "AI-enabled" startups as a distinct investment category because advanced machine learning capability became standard across enterprise health technology architectures. &nbsp;&nbsp; Despite the volume of capital allocated to AI-centric ventures, a divergence has emerged between early-stage valuation metrics and sustainable enterprise defensibility. A significant cohort of healthtech founders remains preoccupied with proving that their products are "AI first" or "AI enough" to satisfy venture capital mandates. This positioning creates substantial strategic risk. An overemphasis on model parameters and algorithmic positioning often diverts attention from the foundational drivers of enterprise software value: workflow depth, system of record status, native Electronic Health Record (EHR) interoperability, regulatory compliance and reimbursable clinical return on investment (ROI). &nbsp;&nbsp; The broader healthtech market in 2026 is defined by extreme capital consolidation. While total capital deployment reached $7.4 billion across 244 transactions in the first half of 2026, deal volume remained flat compared to H1 2025, indicating that institutional investors are writing larger checks for a concentrated group of category winners. Nineteen distinct companies secured 45% of all invested capital across twenty mega-deals valued at $100 million or higher in early 2026. Concurrently, health system Chief Information Officers (CIOs) and enterprise buyers are actively rationalising vendor portfolios, aggressively eliminating standalone "point solutions" and technical debt accumulated during pandemic-era software procurement. &nbsp;&nbsp; Founders who over index on AI messaging risk falling into the "AI-washing" trap. In healthcare, algorithmically intense point solutions that lack deeply embedded workflow tools and proprietary data loops are highly vulnerable to commoditisation by foundation model providers and core EHR incumbents.&nbsp; Sustainable competitive advantage in digital health is achieved not through model parameters alone, but by leveraging technology, whether basic automation, deterministic software, or advanced predictive models, to solve structural operational bottlenecks, secure regulatory clearances, establish billing pathways, and capture sticky workflow real estate.Click here to read the report in full <a href="https://www.healthcare.digital/single-post/strategic-imperatives-for-digital-health-founders-navigating-beyond-ai-hype-to-sustainable-enterpri">https://www.healthcare.digital/single-post/strategic-imperatives-for-digital-health-founders-navigating-beyond-ai-hype-to-sustainable-enterpri</a>

Nelson Advisors

Blog

Nelson Advisors interviewed by Axios

This Week in European HealthTech, MedTech and Health AI: ...

Strategic Analysis of Hugging Face: Valuation Dynamics, E...

Strategic Platform Consolidation in Digital Health: Analy...

Global Consolidation in AI-Enabled Teleradiology: Strateg...

Strategic Imperatives for Digital Health Founders: Naviga...